Trial Profile
An Open-Label, Multinational, Multicenter, Phase IIIB Study to Assess Safety of Rituximab Following Subcutaneous Administration in Patients With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Oct 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Fludarabine; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Registrational
- Acronyms MabRella
- Sponsors Roche
- 29 Sep 2021 Status changed from active, no longer recruiting to completed.
- 21 Jul 2021 Planned End Date changed from 25 Nov 2021 to 10 Feb 2022.
- 21 Jul 2021 Planned primary completion date changed from 25 Nov 2021 to 10 Feb 2022.